摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5H-cyclopenta[c]pyridazine

中文名称
——
中文别名
——
英文名称
5H-cyclopenta[c]pyridazine
英文别名
——
5H-cyclopenta[c]pyridazine化学式
CAS
——
化学式
C7H6N2
mdl
——
分子量
118.14
InChiKey
GYCQFFFAJYZOGN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    25.8
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • PRMT1 inhibitors and uses thereof
    申请人:Epizyme, Inc.
    公开号:US10039748B2
    公开(公告)日:2018-08-07
    Described herein are compounds of Formula (I-a) and (I-b), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT1 activity. Methods of using the compounds for treating PRMT1-mediated disorders are also described.
    本文描述的是式 (I-a) 和 (I-b) 的化合物、其药学上可接受的盐及其药物组合物。本发明的化合物可用于抑制 PRMT1 的活性。还描述了使用这些化合物治疗 PRMT1 介导的疾病的方法。
  • Process for preparing substituted biphenyls
    申请人:BASF SE
    公开号:US10683256B2
    公开(公告)日:2020-06-16
    The present invention relates to a process for preparing substituted biphenyls via Suzuki coupling using specific phosphorus ligands and a solvent mixture containing water, a non-polar organic solvent and a polar aprotic co-solvent.
    本发明涉及一种利用特定配体和含有、非极性有机溶剂和极性钝化助溶剂的混合溶剂,通过铃木偶联制备取代联苯的工艺。
  • Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
    申请人:AbbVie Deutschland GmbH & Co. KG
    公开号:US10836688B2
    公开(公告)日:2020-11-17
    The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.
    本发明涉及一种在有羟基烷基纤维素或烷基纤维素存在的溶液中进行有机反应的方法。
  • Stabilizer composition
    申请人:BASF SE
    公开号:US11001698B2
    公开(公告)日:2021-05-11
    The present invention relates to a stabilizer composition containing at least one sterically hindered amine (HALS) in which the amino group carries a basicity-reducing substituent, at least one antioxidant containing one or more thioether groups and at least one liquid plasticizer containing carboxylate groups. The invention further relates to a polymer composition containing at least one sterically hindered amine (HALS) in which the amino group carries a basicity-reducing substituent, at least one antioxidant containing one or more thioether groups, at least one liquid plasticizer containing carboxylate groups and at least one silyl-terminated polymer, to the use of the stabilizer composition for stabilizing a silyl-terminated polymer or a sealant, adhesive, gasket, knifing filler or coating composition, especially a sealant, adhesive, gasket, knifing filler or coating composition containing a silyl-terminated polymer, against degradation by heat, light and/or oxygen, to the use of the polymer composition as or in a sealant, adhesive, liquid gasket, knifing filler or coating composition, and to a sealant composition or an adhesive composition, or a gasket composition, or a knifing filler composition or a coating composition comprising the polymer composition.
    本发明涉及一种稳定剂组合物,其中至少含有一种基带有还原碱性取代基的立体受阻胺(HALS)、至少一种含有一个或多个醚基团的抗氧化剂和至少一种含有羧酸基团的液体增塑剂。本发明还涉及一种聚合物组合物,该组合物含有至少一种基带有碱性还原取代基的立体受阻胺 (HALS)、至少一种含有一个或多个醚基团的抗氧化剂、至少一种含有羧酸基团的液体增塑剂和至少一种硅烷封端聚合物,该稳定剂组合物可用于稳定硅烷封端聚合物或密封剂、粘合剂、垫圈、刀具填料或涂层组合物、稳定剂组合物用于稳定密封剂、粘合剂、垫片、切削填充剂或涂层组合物,特别是含有硅烷基封端聚合物的密封剂、粘合剂、垫片、切削填充剂或涂层组合物,使其不受热、光和/或氧的影响而降解;稳定聚合物组合物作为密封剂、粘合剂、液体垫片、切削填充剂或涂层组合物或在其中使用;稳定包含聚合物组合物的密封剂组合物、粘合剂组合物、垫片组合物、切削填充剂组合物或涂层组合物。
  • PRMT5 INHIBITORS AND USES THEREOF
    申请人:Epizyme, Inc.
    公开号:US20170210751A1
    公开(公告)日:2017-07-27
    Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof: wherein Y1 is of formula (x) or formula (y):Ring Y is a 5- to 6-membered heteroaryl ring; and V 4 , V 5 , R x , x, y, and n are as defined herein. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
查看更多